Kenneth C. Cundy
Chief Scientific OfficerDr. Kenneth C. Cundy, Ph.D. has been Chief Scientific Officer at Anebulo Pharmaceuticals, Inc. since May 20, 2022. Previously he had been the Chief Scientific Officer of CohBar, Inc. since November 2014 until March 31, 2022. Dr. Cundy served as the Chief Scientific Officer of Xenoport, Inc. from December 2012 until November 2014. Dr. Cundy served as Senior Vice President of Preclinical & Clinical Sciences of Xenoport, Inc. from November 2010 until June 4, 2012. Dr. Cundy served as Senior Vice President of Preclinical Development of Xenoport, Inc., from January 2004 to November 2010. Dr. Cundy was at Xenoport Inc.'s Vice President of biopharmaceutics from 2000 to 2004. From 1992 to 2000, he was senior director of biopharmaceutics at Gilead Sciences. Prior to Gilead Sciences, Dr. Cundy was principal research investigator at Sterling Drug, a pharmaceutical division of Eastman Kodak Company, from 1988 to 1992. He received a B.S. in Pharmacy from the University of Manchester and a Ph.D. in pharmaceutical sciences from the University of Kentucky. He was registered as a pharmacist in the UK. He did postdoctoral training in Biochemistry at the University of California, Berkeley.
Positions
- Company NameAnebulo Pharmaceuticals, Inc.Stock CodeANEBPositionChief Scientific Officer
